Detection of immunologic markers on cancer cells, such as expression of checkpoint proteins or neoantigens (whether a specific neoantigen or assumed neoantigen excess in MSI-H or high-TMB tumors), has enabled basket trials of immune therapies, as discussed above (Friedman et al. 2022, Murciano-Goroff et al. 2020b, Patel et al. 2020, Tateo et al. 2023). The gene discussed is PROS1; the disease is cancer.